Infectious Arthritis or Septic Arthritis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Infectious Arthritis or Septic Arthritis Market Outlook

Thelansis’s “Infectious Arthritis or Septic Arthritis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Infectious Arthritis or Septic Arthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Infectious Arthritis or Septic Arthritis Overview

Septic arthritis also known as Infectious arthritis is joint inflammation secondary to an infectious etiology, usually bacterial but occasionally fungal, mycobacterial, viral, or other uncommon pathogens. Infectious arthritis is usually monoarticular, involving one large joint such as the hip or knee; however, polyarticular septic arthritis involving multiple or smaller joints may also occur. Infectious arthritis is a rare but serious condition that requires urgent attention from an orthopedic specialist. If left untreated, it can cause severe damage to the affected joint, leading to higher rates of illness and death. Early diagnosis and treatment are crucial for preserving joint function. Etiology in Children, Staphylococcus aureus is the most common bacterial pathogen overall. Certain etiologic agents are linked to particular age groups and underlying medical conditions. For children aged 2 to 3 years and under, Kingella kingae is the most prevalent gram-negative bacterial cause. Group B Streptococcus, Staphylococcus aureus, Neisseria gonorrhoea, and gram-negative Bacilli are common among neonates. Staphylococcus aureus is the most common infecting organism in adults, followed by Streptococcus pneumonia. Neisseria gonorrhoeae is a significant concern among sexually active adolescents. Salmonella species infection is commonly seen in patients with sickle cell disease. Patients undergoing prolonged antibiotic therapy are at risk for fungal infections. Joint infection caused by Pseudomonas aeruginosa is often associated with puncture wounds and injection drug use. Among children, the hip joint is the most commonly affected. In high-risk patients, it is recommended to culture Neisseria gonorrhoeae from other sites, such as the oropharynx, urethra, cervix, vagina, or anus, as the organism may not grow sufficiently from cultured synovial fluid.

• The incidence of septic arthritis typically ranges from 2 to 6 cases per 100,000 individuals, but this figure may vary depending on the presence of risk factors.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: